Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8: early-phase trial registry
1 of 7 indexed Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 1 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8: 7 US clinical trials tracked, 1 recruiting.
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Richard Wu, running 1 of these trials.
Enrollment posture brief
Registry condition pathologic-stage-iiic-cutaneous-melanoma-ajcc-v8
OPEN 1 | RECR 14% | LATE 0 | EARLY 6 | RANK #2497 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adverse Drug Events (14% recruiting · 7 trials)
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 lists 1 open slots (14% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 is recruiting below its size-band peers.
1 of 7 indexed trials (14.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 trials is spread across many organizations.
Richard Wu accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 trials plan to enrol fewer than 100 people.
Median target enrolment is 59 among the 7 trials that report a genuine target (sentinel values excluded). 5 of those (71.4%) plan for fewer than 100 participants.
-
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 research is mostly interventional.
6 interventional and 1 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Anusha Kalbasi
NCT04119024
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
ECOG-ACRIN Cancer Research Group
NCT04462406
Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors
M.D. Anderson Cancer Center
NCT04990726
A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma
National Cancer Institute (NCI)
NCT04708418
Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma
Mayo Clinic
NCT03554083
VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma
Emory University
NCT03769155
Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients
Richard Wu
NCT05176470
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 page
7 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Richard Wu sponsors the most Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 trials on record, review their full trial history before evaluating a specific study. See Richard Wu's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 condition card totals 7 registered trials; most-linked intervention Biospecimen Collection; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.